Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,161 Shares of Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 15,161 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the sale, the director now owns 152,396 shares in the company, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Blueprint Medicines Stock Performance

Shares of NASDAQ BPMC opened at $115.63 on Friday. The company has a 50-day simple moving average of $95.28 and a 200-day simple moving average of $95.48. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The company has a market cap of $7.35 billion, a PE ratio of -54.80 and a beta of 0.61. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. During the same period in the previous year, the company earned ($2.20) EPS. Blueprint Medicines’s revenue for the quarter was up 126.5% on a year-over-year basis. On average, equities analysts anticipate that Blueprint Medicines Co. will post -3.67 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on BPMC shares. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Wedbush reissued an “outperform” rating and set a $124.00 price objective (down previously from $135.00) on shares of Blueprint Medicines in a report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, November 15th. UBS Group assumed coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target for the company. Finally, StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $122.72.

Hedge Funds Weigh In On Blueprint Medicines

Several institutional investors have recently added to or reduced their stakes in BPMC. R Squared Ltd acquired a new stake in Blueprint Medicines in the 4th quarter worth about $51,000. KBC Group NV boosted its position in shares of Blueprint Medicines by 63.9% in the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 1,023 shares during the last quarter. Fifth Third Bancorp boosted its position in shares of Blueprint Medicines by 207.5% in the fourth quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 2,075 shares during the last quarter. SG Americas Securities LLC grew its holdings in Blueprint Medicines by 69.7% in the fourth quarter. SG Americas Securities LLC now owns 4,277 shares of the biotechnology company’s stock valued at $373,000 after purchasing an additional 1,756 shares during the period. Finally, Empirical Asset Management LLC acquired a new position in Blueprint Medicines during the fourth quarter worth approximately $2,348,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.